Regulating tumor suppressor genes: post-translational modifications

THE UBIQUITIN SYSTEM

Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Mutation and cancer: statistical study of retinoblastoma

Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612 · see citing works

The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.

Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471 · see citing works

AKT/PKB signaling: navigating downstream

Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · see citing works

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works

The retinoblastoma protein and cell cycle control

Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Integrative Genomic Profiling of Human Prostate Cancer

Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,653 · see citing works

Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks

Olsen, J. V., Blagoev, B., Gnad, F., Maček, B., Kumar, C., Mortensen, P., & Mann, M. (2006) · Cell · doi:10.1016/j.cell.2006.09.026 · Cited by 3,484 · see citing works

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463 · see citing works

A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma

Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 2× · see citing works

Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain

Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559 · see citing works

The regulation of E2F by pRB-family proteins.

Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

Ubiquitin modifications

Swatek, K. N., & Komander, D. (2016) · Cell Research · doi:10.1038/cr.2016.39 · Cited by 2,070 · see citing works

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,067 · see citing works

The functions and regulation of the PTEN tumour suppressor

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926 · see citing works

Programmed Cell Death in Animal Development and Disease

Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915 · see citing works

Putting p53 in context

Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900 · see citing works

Cell cycle proteins as promising targets in cancer therapy

Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,875 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

p53 Has a Direct Apoptogenic Role at the Mitochondria

Mihara, M., Erster, S. H., Zaika, A. I., Petrenko, O., Chittenden, T. D., Pančoška, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,771 · see citing works

The ATM protein kinase: regulating the cellular response to genotoxic stress, and more

Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649 · see citing works

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619 · see citing works

Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome

Kim, W., Bennett, E. J., Huttlin, E. L., Guo, A., Li, J., Possemato, A. P., Sowa, M. E., Rad, R., Rush, A. J., Comb, M. J., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.025 · Cited by 1,582 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

Chk1 and Chk2 kinases in checkpoint control and cancer

Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513 · see citing works

Defining the Human Deubiquitinating Enzyme Interaction Landscape

Sowa, M. E., Bennett, E. J., Gygi, S. P., & Harper, J. W. (2009) · Cell · doi:10.1016/j.cell.2009.04.042 · Cited by 1,512 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Ubiquitination in disease pathogenesis and treatment

Popovic, D., Vucic, D., & Đikić, I. (2014) · Nature Medicine · doi:10.1038/nm.3739 · Cited by 1,405 · see citing works

The tripartite motif family identifies cell compartments

Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., Cainarca, S., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.9.2140 · Cited by 1,366 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 1× · see citing works

Post-translational modification of p53 in tumorigenesis

Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270 · see citing works

Gatekeepers and caretakers

Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386761a0 · Cited by 1,240 · see citing works

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · see citing works

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1819 · Cited by 1,233 · see citing works

Proteasome-Independent Functions of Ubiquitin in Endocytosis and Signaling

Mukhopadhyay, D., & Riezman, H. (2007) · Science · doi:10.1126/science.1127085 · Cited by 1,221 · see citing works

DNA damage activates p53 through a phosphorylation–acetylation cascade

Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · see citing works

DNA damage and the balance between survival and death in cancer biology

Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189 · see citing works

The Multiple Roles of PTEN in Tumor Suppression

Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182 · see citing works

Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation

Xu, P., Duong, D. M., Seyfried, N. T., Cheng, D., Xie, Y., Robert, J., Rush, A. J., Hochstrasser, M., Finley, D. J., & Peng, J. (2009) · Cell · doi:10.1016/j.cell.2009.01.041 · Cited by 1,125 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly

Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H. D., Mayer, T. U., & Jentsch, S. (1999) · Cell · doi:10.1016/s0092-8674(00)80574-7 · Cited by 1,056 · see citing works

Mechanisms of Deubiquitinase Specificity and Regulation

Mevissen, T. E. T., & Komander, D. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044916 · Cited by 1,035 · see citing works

Principles of Tumor Suppression

Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,028 · see citing works

Tenets of PTEN Tumor Suppression

Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,027 · see citing works

Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization

Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. J. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,027 · see citing works

Correction of a pathogenic gene mutation in human embryos

Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., et al. (2017) · Nature · doi:10.1038/nature23305 · Cited by 969 · cited 1× · see citing works

BRCA1 and BRCA2: 1994 and beyond

Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951 · see citing works

APC, Signal transduction and genetic instability in colorectal cancer

Fodde, R., Smits, R., & Clevers, H. (2001) · Nature Reviews Cancer · doi:10.1038/35094067 · Cited by 937 · see citing works

Targeting CDK4 and CDK6: From Discovery to Therapy

Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936 · see citing works

p53 ubiquitination: Mdm2 and beyond

Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924 · see citing works

ARF family G proteins and their regulators: roles in membrane transport, development and disease

Donaldson, J. G., & Jackson, C. L. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3117 · Cited by 914 · see citing works

Regulation of the specific DNA binding function of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 905 · see citing works

A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles

Wagner, S., Beli, P., Weinert, B. T., Nielsen, M. L., Cox, J., Mann, M., & Choudhary, C. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.013284 · Cited by 889 · see citing works

The long tail of oncogenic drivers in prostate cancer

PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 873 · see citing works

p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression

Lin, T., Chao, C., Saito, S., Mazur, S. J., Murphy, M. E., Appella, E., & Xu, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1211 · Cited by 859 · see citing works

Regulation of p53 activity through lysine methylation

Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., McKinney, K. M., Tempst, P., Prives, C. L., Gamblin, S. J., et al. (2004) · Nature · doi:10.1038/nature03117 · Cited by 820 · see citing works

p53 is regulated by the lysine demethylase LSD1

Huang, J. L., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 820 · see citing works

Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications

Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 817 · see citing works

Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2

Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1× · see citing works

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802 · see citing works

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities

Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.030 · Cited by 799 · see citing works

p53: oncogene or anti-oncogene?Preprint

Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 796 · see citing works

The broken cycle: E2F dysfunction in cancer

Kent, L. N., & Leone, G. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 786 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B. C., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 783 · see citing works

Phosphorylation of the PTEN Tail Regulates Protein Stability and Function

Vázquez, F., Ramaswamy, S., Nakamura, N., & Sellers, W. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5010-5018.2000 · Cited by 777 · see citing works

The p53–Mdm2 module and the ubiquitin system

Michael, D., & Oren, M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 759 · see citing works

Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells.

Goldstein, G., Scheid, M. P., Hämmerling, U., Schlesinger, D. H., Niall, H. D., & Boyse, E. A. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.1.11 · Cited by 752 · see citing works

The retinoblastoma tumour suppressor in development and cancer

Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738 · see citing works

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking

Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738 · see citing works

Ubiquitylation and cell signaling

Haglund, K., & Đikić, I. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600808 · Cited by 736 · see citing works

TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases

Meroni, G., & Diez‐Roux, G. (2005) · BioEssays · doi:10.1002/bies.20304 · Cited by 731 · see citing works

NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN

Wang, X., Trotman, L. C., Koppie, T. M., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument‐Bromage, H., Tempst, P., Cordon‐Cardo, C., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.039 · Cited by 720 · see citing works

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 717 · see citing works

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 716 · cited 2× · see citing works

The ubiquitin ligase COP1 is a critical negative regulator of p53

Dornan, D., Wertz, I. E., Shimizu, H., Arnott, D. P., Frantz, G. D., Dowd, P., Rourke, K. O., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 700 · see citing works

Structural Biology of the Tumor Suppressor p53

Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 699 · see citing works

Binding and modulation of p53 by p300/CBP coactivators

Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J. A., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693 · see citing works

A dynamic role of HAUSP in the p53-Mdm2 pathway

Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679 · see citing works

Recruitment of p300/CBP in p53-Dependent Signal Pathways

Avantaggiati, M. L., Ogryzko, V. V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 668 · see citing works

Crystal Structure of a UBP-Family Deubiquitinating Enzyme in Isolation and in Complex with Ubiquitin Aldehyde

Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J.-W., Gu, W. J., Cohen, R. E., & Shi, Y. (2002) · Cell · doi:10.1016/s0092-8674(02)01199-6 · Cited by 648 · see citing works

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · see citing works

SUMO‐1 modification activates the transcriptional response of p53

Rodríguez, M. S., Desterro, J. M. P., Laı́n, S., Midgley, C., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639 · see citing works

USP10 Regulates p53 Localization and Stability by Deubiquitinating p53

Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 2× · see citing works

The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus

Torres, J., & Pulido, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009134200 · Cited by 630 · see citing works

Repression of p53 activity by Smyd2-mediated methylation

Huang, J. L., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. A., Kubicek, S., Opravil, S., Jenuwein, T., & Berger, S. L. (2006) · Nature · doi:10.1038/nature05287 · Cited by 626 · see citing works

Why are there hotspot mutations in the TP53 gene in human cancers?

Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R., & Chan, C. S. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.180 · Cited by 609 · see citing works

Tumour suppression by p53: a role for the DNA damage response?

Meek, D. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2716 · Cited by 604 · see citing works

Divorcing ARF and p53: an unsettled case

Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595 · see citing works

PTEN: Tumor Suppressor and Metabolic Regulator

Chen, C.-Y., Chen, J., He, L., & Stiles, B. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00338 · Cited by 589 · see citing works

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

Venot, Q., Blanc, T., Hadj-Rabia, S., Berteloot, L., Ladraa, S., Huyen, J. D. V., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 588 · see citing works

Chromatin replication and epigenome maintenance

Alabert, C., & Groth, A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3288 · Cited by 586 · see citing works

Adenoviral ElA-associated protein p300 as a functional homologue of the transcriptional co-activator CBP

Lundblad, J. R., Kwok, R. P. S., Laurance, M. E., Harter, M. L., & Goodman, R. H. (1995) · Nature · doi:10.1038/374085a0 · Cited by 585 · see citing works

Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13777 · Cited by 583 · see citing works

p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2

Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., & Yao, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1331 · Cited by 582 · see citing works

Molecular mechanisms underlying RB protein function

Dick, F. A., & Rubin, S. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3567 · Cited by 570 · see citing works

Ubiquitin chain diversity at a glance

Akutsu, M., Đikić, I., & Bremm, A. (2016) · Journal of Cell Science · doi:10.1242/jcs.183954 · Cited by 555 · see citing works

ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor

Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. J. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 539 · see citing works

Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA

Wang, M., Mao, C., Ouyang, L., Liu, Y., Lai, W., Liu, N., Shi, Y., Chen, L., Xiao, D., Yu, F., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0304-y · Cited by 530 · see citing works

p53 post-translational modification: deregulated in tumorigenesis

Dai, C., & Gu, W. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523 · see citing works

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6

Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513 · see citing works

Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1

Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S. E., Scheffner, M., & Sal, G. D. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6462 · Cited by 512 · see citing works

Critical role of FOXO3a in carcinogenesis

Liu, Y., Ao, X., Ding, W., Ponnusamy, M., Wu, W., Hao, X., Yu, W., Wang, Y., Li, P., & Wang, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0856-3 · Cited by 508 · see citing works

Acetylation of p53 inhibits its ubiquitination by Mdm2

Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503 · see citing works

CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest

Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 495 · see citing works

A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53

Mao, C., Wang, X., Liu, Y., Wang, M., Yan, B., Jiang, Y., Shi, Y., Shen, Y., Liu, X., Lai, W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3454 · Cited by 493 · see citing works

Arginine methylation regulates the p53 response

Jansson, M., Durant, S., Cho, E., Sheahan, S., Edelmann, M. J., Kessler, B., & Thangue, N. L. (2008) · Nature Cell Biology · doi:10.1038/ncb1802 · Cited by 492 · see citing works

Posttranslational Modification of p53: Cooperative Integrators of FunctionPreprint

Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 487 · see citing works

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

George, S., Miao, D., Demetri, G. D., Adeegbe, D. O., Rodig, S. J., Shukla, S. A., Lipschitz, M., Amin‐Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 476 · see citing works

PTEN: Multiple Functions in Human Malignant Tumors

Milella, M., Falcone, I., Conciatori, F., Incani, U. C., Curatolo, A. D., Inzerilli, N., Nuzzo, C. M. A., Vaccaro, V., Vari, S., Cognetti, F., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00024 · Cited by 469 · see citing works

Modulation of p53 Function by SET8-Mediated Methylation at Lysine 382

Shi, X., Kachirskaia, I., Yamaguchi, H., West, L. E., Wen, H., Wang, E. W., Dutta, S. M., Appella, E., & Gozani, O. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.012 · Cited by 463 · see citing works

A General Theory of Carcinogenesis

Comings, D. E. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.12.3324 · Cited by 462 · see citing works

Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7

Lee, J., Russo, A. A., & Pavletich, N. P. (1998) · Nature · doi:10.1038/36038 · Cited by 459 · see citing works

ATM Mutations in Cancer: Therapeutic Implications

Choi, M. P., Kipps, T. J., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 456 · see citing works

Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300

Grossman, S. R., Deato, M. D. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., & Livingston, D. M. (2003) · Science · doi:10.1126/science.1080386 · Cited by 454 · see citing works

Involvement of PIAS1 in the Sumoylation of Tumor Suppressor p53

Kahyo, T., Nishida, T., & Yasuda, H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00349-5 · Cited by 449 · see citing works

Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells

Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446 · see citing works

RB1 : a prototype tumor suppressor and an enigmaPreprint

Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 437 · see citing works

Let Me Count the Ways

Walther, J. B., Loh, T., & Granka, L. A. (2005) · Journal of Language and Social Psychology · doi:10.1177/0261927x04273036 · Cited by 436 · see citing works

Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains

Emmerich, C. H., Ordureau, A., Strickson, S., Arthur, J. S. C., Pedrioli, P. G. A., Komander, D., & Cohen, P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314715110 · Cited by 425 · see citing works

2011: the immune hallmarks of cancer

Cavallo, F., Giovanni, C. D., Nanni, P., Forni, G., & Lollini, P. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 417 · see citing works

The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network

Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 408 · see citing works

Two distinct modes for propagation of histone PTMs across the cell cyclePreprint

Alabert, C., Barth, T. K., Reverón-Gómez, N., Sidoli, S., Schmidt, A., Jensen, O. N., Imhof, A., & Groth, A. (2015) · Genes & Development · doi:10.1101/gad.256354.114 · Cited by 404 · see citing works

PTEN, more than the AKT pathway

Blanco‐Aparicio, C., Renner, O., Martínez-Leal, J. F., & Carnero, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm052 · Cited by 403 · see citing works

Drugs and Lactation Database: LactMed

Chelf, C. J. (2012) · Journal of Electronic Resources in Medical Libraries · doi:10.1080/15424065.2012.735134 · Cited by 401 · see citing works

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Xu, C., Brainson, C. F., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 394 · see citing works

Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation

Rodríguez, M. S., Desterro, J. M. P., Laı́n, S., Lane, D. P., & Hay, R. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8458-8467.2000 · Cited by 386 · see citing works

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384 · see citing works

A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation

Zhang, Y., & Xiong, Y. (2001) · Science · doi:10.1126/science.1058637 · Cited by 378 · cited 1× · see citing works

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378 · see citing works

The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication

Tarsounas, M., & Sung, P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0218-z · Cited by 366 · see citing works

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Ma, C. X., Gao, F., Luo, J. R., Northfelt, D., Goetz, M. P., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F. O., Suresh, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3206 · Cited by 360 · see citing works

The role of PTEN signaling perturbations in cancer and in targeted therapy

Keniry, M. E., & Parsons, R. E. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 358 · see citing works

Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1

Nakada, S., Tai, I., Panier, S., Al-Hakim, A., Iemura, S.-I., Juang, Y.-C., O’Donnell, L., Kumakubo, A., Munro, M., Sicheri, F., et al. (2010) · Nature · doi:10.1038/nature09297 · Cited by 357 · see citing works

Mechanism of action of the immunosuppressant rapamycin

Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 356 · see citing works

Stress Signals Utilize Multiple Pathways To Stabilize p53

Ashcroft, M. A., Taya, Y., & Vousden, K. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3224-3233.2000 · Cited by 356 · see citing works

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

Hu, Q., Ye, Y., Chan, L.-C., Li, Y., Liang, K., Lin, A., Egranov, S. D., Zhang, Y., Xia, W., Gong, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0400-7 · Cited by 353 · see citing works

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351 · see citing works

Tailoring to RB: tumour suppressor status and therapeutic response

Knudsen, E. S., & Knudsen, K. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2401 · Cited by 345 · see citing works

Protein Language: Post-Translational Modifications Talking to Each Other.

Vu, L. D., Gevaert, K., & Smet, I. D. (2018) · Trends in Plant Science · doi:10.1016/j.tplants.2018.09.004 · Cited by 340 · see citing works

Principles of Ubiquitin-Dependent Signaling

Oh, E., Akopian, D., & Rape, M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062802 · Cited by 339 · see citing works

The post-translational modification, SUMOylation, and cancer (Review)

Han, Z., Feng, Y.-H., Gu, B.-H., Li, Y., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 337 · see citing works

XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.

Asselin, É., Mills, G. B., & Tsang, B. K. (2001) · PubMed · Cited by 336 · see citing works

Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview

Wang, L., Wu, C., Rajasekaran, N., & Shin, Y. K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495956 · Cited by 334 · see citing works

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

Lee, Y.-R., Chen, M., Lee, J. D., Zhang, J., Lin, S., Fu, T., Chen, H., Ishikawa, T., Chiang, S.-Y., Katon, J. M., et al. (2019) · Science · doi:10.1126/science.aau0159 · Cited by 331 · see citing works

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space

Klughammer, J., Kiesel, B., Roetzer-Pejrimovsky, T., Fortelny, N., Nemc, A., Nenning, K., Furtner, J., Sheffield, N. C., Datlinger, P., Peter, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0156-x · Cited by 326 · see citing works

A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival

Hopkins, B. D., Fine, B. M., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J. M., Pappas, K., Yu, J. S., Hodakoski, C., Mense, S. M., et al. (2013) · Science · doi:10.1126/science.1234907 · Cited by 325 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 321 · see citing works

The next level of complexity: Crosstalk of posttranslational modifications

Venne, A. S., Kollipara, L., & Zahedi, R. P. (2013) · PROTEOMICS · doi:10.1002/pmic.201300344 · Cited by 320 · see citing works

Assembly and Function of Heterotypic Ubiquitin Chains in Cell-Cycle and Protein Quality Control

Yau, R. G., Dörner, K., Castellanos, E. R., Haakonsen, D. L., Werner, A. A., Wang, N., Yang, X. W., Martinez-Martín, N., Matsumoto, M. L., Dixit, V. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.040 · Cited by 315 · see citing works

USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development

Lin, Z., Yang, H., Kong, Q., Li, J., Lee, S.-M., Gao, B., Dong, H., Wei, J., Song, J., Zhang, D. D., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.024 · Cited by 315 · see citing works

Rb regulates fate choice and lineage commitment in vivo

Calo, E., Quintero-Estades, J. A., Danielian, P. S., Nedelcu, S., Berman, S. D., & Lees, J. A. (2010) · Nature · doi:10.1038/nature09264 · Cited by 313 · see citing works

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311 · see citing works

Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters

Loughery, J., Cox, M. L., Smith, L. M., & Meek, D. W. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku501 · Cited by 308 · see citing works

WWP2 is an E3 ubiquitin ligase for PTEN

Maddika, S., Kavela, S., Rani, N., Palicharla, V. R., Pokorny, J. L., Sarkaria, J. N., & Chen, J. (2011) · Nature Cell Biology · doi:10.1038/ncb2240 · Cited by 306 · see citing works

Mechanism of Phosphorylation-Dependent Binding of APC to β-Catenin and Its Role in β-Catenin Degradation

Ha, N., Tonozuka, T., Stamos, J. L., Choi, H., & Weis, W. I. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.010 · Cited by 304 · see citing works

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · see citing works

Trim24 targets endogenous p53 for degradation

Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292 · see citing works

The regulation of protein phosphorylation

Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 292 · see citing works

Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain

Chow, L. M. L., Endersby, R., Zhu, X., Rankin, S. L., Qu, C., Zhang, J., Broniscer, A., Ellison, D. W., & Baker, S. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.039 · Cited by 291 · see citing works

Regulation of the p53 response and its relationship to cancer

Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 291 · see citing works

Is there a code embedded in proteins that is based on post-translational modifications?

Sims, R. J., & Reinberg, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2502 · Cited by 289 · see citing works

CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?

Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2251 · Cited by 287 · see citing works

Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate

Knights, C. D., Catania, J., Giovanni, S. D., Muratoglu, S. C., Perez, R. E., Swartzbeck, A., Quong, A. A., Zhang, X., Beerman, T. A., Pestell, R. G., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200512059 · Cited by 284 · see citing works

Acetylation control of the retinoblastoma tumour-suppressor protein

Chan, H. M., Krstic–Demonacos, M., Smith, L. M., Demonacos, C., & Thangue, N. B. L. (2001) · Nature Cell Biology · doi:10.1038/35083062 · Cited by 282 · see citing works

The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2

Stevenson, L. F., Sparks, A., Allende‐Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601567 · Cited by 280 · see citing works

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Hamid, A., Gray, K. P., Shaw, G., MacConaill, L. E., Evan, C. P., Bernard, B. D., Loda, M. F., Corcoran, N. M., Allen, E. M. V., Choudhury, A. D., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.045 · Cited by 276 · see citing works

Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’

Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E.-K., Toriyama, S., Ikeda, R., Zhang, L., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601490 · Cited by 275 · see citing works

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN

Rahdar, M., Inoue, T., Meyer, T., Zhang, J., Vázquez, F., & Devreotes, P. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811212106 · Cited by 266 · see citing works

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 261 · see citing works

Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.

Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F. A. S., Ovaa, H., Abraham, T. E., Dirks, R. W., & Jochemsen, A. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.024 · Cited by 260 · see citing works

Cooperative Phosphorylation of the Tumor Suppressor Phosphatase and Tensin Homologue (PTEN) by Casein Kinases and Glycogen Synthase Kinase 3β

Al-Khouri, A. M., Ma, Y., Togo, S. H., Williams, S., & Mustelin, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503045200 · Cited by 254 · see citing works

Structure of the Rb C-Terminal Domain Bound to E2F1-DP1: A Mechanism for Phosphorylation-Induced E2F Release

Rubin, S. M., Gall, A.-L., Zheng, N., & Pavletich, N. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.044 · Cited by 253 · see citing works

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment

Hoffmann, K., Berger, H., Kulbe, H., Thillainadarasan, S., Mollenkopf, H., Żemojtel, T., TAUBE, E. T., Darb‐Esfahani, S., Mangler, M., Sehouli, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104013 · Cited by 252 · see citing works

The management of retinoblastoma

Fabian, I. D., Onadim, Z., Karaa, E. K., Duncan, C., Chowdhury, T., Scheimberg, I. B., Ohnuma, S., Reddy, M. A., & Sagoo, M. S. (2018) · Oncogene · doi:10.1038/s41388-017-0050-x · Cited by 251 · see citing works

Structural Basis of Competitive Recognition of p53 and MDM2 by HAUSP/USP7: Implications for the Regulation of the p53–MDM2 Pathway

Hu, M., Gu, L., Li, M., Jeffrey, P. D., Gu, W., & Shi, Y. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040027 · Cited by 251 · see citing works

The mechanism of OTUB1-mediated inhibition of ubiquitination

Wiener, R., Zhang, X., Wang, T., & Wolberger, C. (2012) · Nature · doi:10.1038/nature10911 · Cited by 248 · see citing works

Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors

Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247 · see citing works

Molecular pathways: CDK4 inhibitors for cancer therapy

Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245 · see citing works

Deciphering the retinoblastoma protein phosphorylation code

Rubin, S. M. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.007 · Cited by 244 · see citing works

Protein standard absolute quantification (PSAQ) method for the measurement of cellular ubiquitin pools

Kaiser, S. E., Riley, B. E., Shaler, T. A., Trevino, R., Becker, C. H., Schulman, H., & Kopito, R. R. (2011) · Nature Methods · doi:10.1038/nmeth.1649 · Cited by 242 · see citing works

E4F1 Is an Atypical Ubiquitin Ligase that Modulates p53 Effector Functions Independently of Degradation

Cam, L. L., Linares, L. K., Paul, C., Julien, E., Lacroix, M., Hatchi, E., Triboulet, R., Bossis, G., Shmueli, A., Rodríguez, M. S., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.031 · Cited by 241 · see citing works

The genomic landscape of tuberous sclerosis complex

Martin, K. R., Zhou, W., Bowman, M. J., Shih, J., Au, K. S., Dittenhafer-Reed, K. E., Sisson, K. A., Koeman, J., Weisenberger, D. J., Cottingham, S. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15816 · Cited by 238 · see citing works

Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity

Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · see citing works

Surf the Post-translational Modification Network of p53 Regulation

Gu, B., & Zhu, W. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4283 · Cited by 234 · see citing works

DUBs, Hypoxia, and Cancer

Mennerich, D., Kubaichuk, K. I., & Kietzmann, T. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.08.005 · Cited by 232 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

p53 signaling in cancer progression and therapy

Marei, H. E. S., Thani, A. A. A., Afifi, N. M., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 602 · see citing works

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442 · see citing works

Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response

Snyder, N. A., & Silva, G. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101077 · Cited by 352 · see citing works

Deubiquitinase-targeting chimeras for targeted protein stabilization

Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344 · see citing works

Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery

Kwon, Y. W., Jo, H.-S., Bae, S., Seo, Y., Song, P., Song, M., & Yoon, J. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.747333 · Cited by 270 · see citing works

Pathological implication of protein post-translational modifications in cancer

Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 272 · see citing works

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 269 · see citing works

Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis

Xiao, Y., Bi, M., Guo, H., & Li, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104001 · Cited by 256 · see citing works

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 231 · see citing works

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

Rah, B., Rather, R. A., Bhat, G. R., Baba, A. B., Mushtaq, I., Farooq, M., Yousuf, T., Dar, S. B., Parveen, S., Hassan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.821344 · Cited by 202 · see citing works

A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy

Andleeb, A., Andleeb, A., Asghar, S., Zaman, G., Tariq, M., Mehmood, A., Nadeem, M., Hano, C., Lorenzo, J. M., & Abbasi, B. H. (2021) · Cancers · doi:10.3390/cancers13112818 · Cited by 173 · see citing works

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?

Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Guerini‐Rocco, E., Criscitiello, C., Malapelle, U., & Invernizzi, M. (2020) · Genes · doi:10.3390/genes11070719 · Cited by 167 · see citing works

Posttranslational Modifications in Ferroptosis

Wei, X., Yi, X., Zhu, X., & Jiang, D. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8832043 · Cited by 165 · see citing works

Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances

Shen, C., Jiang, X., Li, M., & Luo, Y. (2023) · Cancers · doi:10.3390/cancers15020533 · Cited by 158 · see citing works

The landscape of T cell antigens for cancer immunotherapy

Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 130 · see citing works

Altered glycosylation in cancer: molecular functions and therapeutic potential

Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, W., Han, Y., Oyang, L., Lin, J., Shen, M., Wang, J., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12610 · Cited by 131 · see citing works

Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function

Gao, L., Wu, Z., Assaraf, Y. G., Chen, Z., & Wang, L. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100770 · Cited by 118 · see citing works

Oncogenes and tumor suppressor genes: functions and roles in cancers

Dakal, T. C., Dhabhai, B., Pant, A., Moar, K., Chaudhary, K., Yadav, V., Ranga, V., Sharma, N. K., Kumar, A., Maurya, P. K., et al. (2024) · MedComm · doi:10.1002/mco2.582 · Cited by 125 · see citing works

Genetic expression in cancer research: Challenges and complexity

Liu, H., Guo, Z., & Wang, P. (2024) · Gene Reports · doi:10.1016/j.genrep.2024.102042 · Cited by 104 · see citing works

Therapeutic Potential of Targeting the SUMO Pathway in Cancer

Kukkula, A., Ojala, V. K., Mendez, L., Sistonen, L., Elenius, K., & Sundvall, M. (2021) · Cancers · doi:10.3390/cancers13174402 · Cited by 92 · see citing works

Applications of graphene-based electrochemical and optical biosensors in early detection of cancer biomarkers

Arshad, F., Nabi, F., Iqbal, S., & Khan, R. H. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112356 · Cited by 91 · see citing works

AMPKα1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma

Wang, Z., Wang, Y., Shen, N., Liu, Y., Xu, X., Zhu, R., Jiang, H., Wu, X., Wei, Y., & Tang, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216619 · Cited by 88 · see citing works

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Ma, Q., Zhang, W., Wu, K., & Shi, L. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02218-1 · Cited by 92 · see citing works

Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases

Yang, B., Lin, Y., Huang, Y., Shen, Y.-Q., & Chen, Q. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103032 · Cited by 90 · see citing works

Ferroptosis: an important player in the inflammatory response in diabetic nephropathy

Li, J., Li, L., Zhang, Z., Chen, P., Shu, H., Yang, C., Chu, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294317 · Cited by 82 · see citing works

Liposomes for the Treatment of Brain Cancer—A Review

Raju, R., Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2023) · Pharmaceuticals · doi:10.3390/ph16081056 · Cited by 76 · see citing works

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

Mukai, H., Shimizu, C., Masuda, N., Ohtani, S., Ohno, S., Takahashi, M., Yamamoto, Y., Nishimura, R., Sato, N., Ohsumi, S., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1353-9 · Cited by 72 · see citing works

p53: From Fundamental Biology to Clinical Applications in Cancer

Capuozzo, M., Santorsola, M., Bocchetti, M., Perri, F., Cascella, M., Granata, V., Celotto, V., Gualillo, O., Cossu, A. M., Nasti, G., et al. (2022) · Biology · doi:10.3390/biology11091325 · Cited by 70 · see citing works

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway

Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69 · see citing works

Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment

Mafi, A., Rahmati, A., Aghdam, Z. B., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 66 · see citing works

Acetylation targeting chimera enables acetylation of the tumor suppressor p53

Kabir, M., Sun, N., Hu, X., Martin, T. C., Yi, J., Zhong, Y., Xiong, Y., Kaniskan, H. Ü., Gu, W., Parsons, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04640 · Cited by 65 · see citing works

Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach

Mukherjee, A. G., Wanjari, U. R., Namachivayam, A., Murali, R., Prabakaran, D. S., Ganesan, R., Renu, K., Dey, A., Vellingiri, B., Ramanathan, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10091493 · Cited by 67 · see citing works

GINS4 suppresses ferroptosis by antagonizing p53 acetylation with Snail

Chen, L., Cai, Q., Yang, R., Wang, H., Ling, H., Li, T., Liu, N., Wang, Z., Sun, J., Tao, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219585120 · Cited by 64 · see citing works

Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent

Zhou, C., Huang, Y., Nie, S., Zhou, S., Gao, X., & Chen, G. (2023) · European journal of medical research · doi:10.1186/s40001-023-01271-8 · Cited by 63 · see citing works

PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer

Fan, Y., Wang, Y., Dan, W., Zhang, Y., Nie, L., Ma, Z., Zhuang, Y., Liu, B., Li, M., Liu, T., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01610-3 · Cited by 62 · see citing works

PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma

Liu, Y., Ouyang, L., Mao, C., Chen, Y., Li, T., Liu, N., Wang, Z., Lai, W., Zhou, Y., Cao, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02370-2 · Cited by 58 · see citing works

Natural antisense transcripts in the biological hallmarks of cancer: powerful regulators hidden in the dark

Zhao, S., Zhang, X., Chen, S., & Zhang, S. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01700-0 · Cited by 58 · see citing works

Advancement in Biopolymer Assisted Cancer Theranostics

Bhattacharya, T., Preetam, S., Ghosh, B., Chakrabarti, T., Chakrabarti, P., Samal, S., & Thorat, N. D. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00458 · Cited by 42 · see citing works

Liquid-liquid phase separation in DNA double-strand breaks repair

Wang, Y., Zhao, W.-W., Shi, J., Wan, X., Zheng, J., & Fan, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06267-0 · Cited by 59 · see citing works

p53 deacetylation alleviates calcium oxalate deposition-induced renal fibrosis by inhibiting ferroptosis

Ye, Z., Xia, Y., Li, L., Li, B., Chen, L., Yu, W., Ruan, Y., Rao, T., Zhou, X., & Fan, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114925 · Cited by 53 · see citing works

Multiple aspects of matrix stiffness in cancer progression

Mancini, A., Gentile, M. T., Pentimalli, F., Cortellino, S., Grieco, M., & Giordano, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1406644 · Cited by 52 · see citing works

PDLIM2: Signaling pathways and functions in cancer suppression and host immunity

Guo, Z. S., & Qu, Z. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188630 · Cited by 50 · see citing works

Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

Yadollahi, P., Jeon, Y., Ng, W. L., & Choi, I. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.241 · Cited by 45 · see citing works

GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer

Long, Y., Guo, J., Chen, J., Sun, J., Wang, H., Peng, X., Wang, Z., Lai, W., Liu, N., Shu, L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01224-3 · Cited by 45 · see citing works

TRIM21‐Promoted FSP1 Plasma Membrane Translocation Confers Ferroptosis Resistance in Human Cancers

Gong, J., Liu, Y., Wang, W., He, R., Xia, Q., Chen, L., Zhao, C., Gao, Y., Shi, Y., Bai, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202302318 · Cited by 45 · see citing works

MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation

Li, M., Shi, M., Hu, C., Chen, B., & Li, S. (2021) · Oncogene · doi:10.1038/s41388-021-01816-3 · Cited by 45 · see citing works

A Bibliometric Analysis Based on Web of Science: Current Perspectives and Potential Trends of SMAD7 in Oncology

Huang, X., Yang, Z., Zhang, J., Wang, R., Fan, J., Zhang, H., Xu, R., Li, X., Yu, S., Long, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.712732 · Cited by 45 · see citing works

The Functional Roles of ISG15/ISGylation in Cancer

Yin, Y., Qin, H., Li, H., Shi, W., Bao, L., Xu, S., Yin, J., & Zheng, L. (2023) · Molecules · doi:10.3390/molecules28031337 · Cited by 43 · see citing works

TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer

Saldías, M. P., Maureira, D., Orellana‐Serradell, O., Silva, I., Lavanderos, B. J., Cruz, P., Torres, C., Cáceres, M., & Cerda, O. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621614 · Cited by 42 · see citing works

Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor

Liu, N., Ling, R., Tang, X., Yu, Y., Zhou, Y., & Chen, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847701 · Cited by 42 · see citing works

Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells

Tu, Y., Xu, L., Fu, G., Wang, J., Xia, P., Tao, Z., Ye, Y., Hu, J., Cai, W., Zhu, H., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01494-8 · Cited by 48 · see citing works

Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy

Chen, F., Wang, J., Wu, Y. C., Gao, Q., & Zhang, S. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.822449 · Cited by 41 · see citing works

p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act

Guo, Y., Tang, Y., Lu, G., & Gu, J. (2023) · Nutrients · doi:10.3390/nu15102259 · Cited by 39 · see citing works

Post‐Translational Modifications of RNA‐Modifying Proteins in Cellular Dynamics and Disease Progression

Lin, Y., Lin, P., Lu, Y., Zheng, J., Zheng, Y., Huang, X., Zhao, X., & Cui, L. (2024) · Advanced Science · doi:10.1002/advs.202406318 · Cited by 39 · see citing works

Regulation and Function of the cGAS-STING Pathway: Mechanisms, Post-Translational Modifications, and Therapeutic Potential in Immunotherapy

Chen, Y., Yue, S., Yu, L., Cao, J., Liu, Y., Deng, A., Lu, Y., Yang, J., Li, Y., Du, J., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s501773 · Cited by 39 · see citing works

Post-Translational Modifications That Drive Prostate Cancer Progression

Samaržija, I. (2021) · Biomolecules · doi:10.3390/biom11020247 · Cited by 39 · see citing works

Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer

Amani, J., Gorjizadeh, N., Younesi, S., Najafi, M., Ashrafi, A. M., Irian, S., Gorjizadeh, N., & Azizian, K. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103103 · Cited by 39 · see citing works

The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy

Xie, D., Li, G., Zheng, Z., Zhang, X., Wang, S., Jiang, B., Li, X., Wang, X., & Wu, G. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101335 · Cited by 38 · see citing works

Long noncoding RNA Linc02023 regulates PTEN stability and suppresses tumorigenesis of colorectal cancer in a PTEN-dependent pathway

Wang, Q., Feng, Y., Peng, W., Ji, D., Zhang, Z., Qian, W., Li, J., Gu, Q., Zhang, D., Tang, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.041 · Cited by 38 · see citing works

UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions

Wang, X., Lv, X., Ma, J., & Xu, G. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108680 · Cited by 37 · see citing works

Post-translational Modifications of the p53 Protein and the Impact in Alzheimer’s Disease: A Review of the Literature

Clark, J., Kayed, R., Abate, G., Uberti, D. L., Kinnon, P., & Piccirella, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.835288 · Cited by 37 · see citing works

p53 at the crossroad between mitochondrial reactive oxygen species and necroptosis

Rius‐Pérez, S. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.022 · Cited by 37 · see citing works

Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression

Pi, Y., Feng, Q., Sun, F., Wang, Z., Zhao, Y., Chen, D., Liu, Y., & Lou, G. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01226-w · Cited by 36 · see citing works

Lactylome analyses suggest systematic lysine-lactylated substrates in oral squamous cell carcinoma under normoxia and hypoxia

Song, F., Hou, C., Huang, Y., Liang, J., Cai, H., Tian, G., Jiang, Y., Wang, Z., & Hou, J. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111228 · Cited by 34 · see citing works

Advancements in CRISPR/Cas systems for disease treatment

Xu, Y., Le, H., Wu, Q., Wang, N., & Gong, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.007 · Cited by 35 · see citing works

Regulation of Inflammatory Cell Death by Phosphorylation

Xu, W., & Huang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.851169 · Cited by 34 · see citing works

The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer

Padariya, M., Jooste, M.-L., Hupp, T., Fåhraeus, R., Vojtesek, B., Vollrath, F., Kalathiya, U., & Karakostis, K. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac149 · Cited by 33 · see citing works

BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer

Ismail, T., Alzneika, S., Riguene, E., Al-Maraghi, S., Alabdulrazzak, A., Al-Khal, N., Fetais, S., Thanassoulas, A., Farsi, H. F. A., & Nomikos, M. (2024) · Pharmaceuticals · doi:10.3390/ph17030333 · Cited by 32 · see citing works

Post-Translational Modification of ZEB Family Members in Cancer Progression

Park, M. K., Lee, H., & Lee, C. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315127 · Cited by 32 · see citing works

Lenvatinib resistance mechanism and potential ways to conquer

Bo, W., & Chen, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1153991 · Cited by 32 · see citing works

Biomedical generative pre-trained based transformer language model for age-related disease target discovery

Zagirova, D., Pushkov, S., Leung, G. H. D., Liu, B. H. M., Urban, A., Sidorenko, D., Kalashnikov, A., Kozlova, E., Naumov, V., Pun, F. W., et al. (2023) · Aging · doi:10.18632/aging.205055 · Cited by 32 · see citing works

The role of acetylation and deacetylation in cancer metabolism

Wang, C., & Ma, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70145 · Cited by 31 · see citing works

Exploring the Frontier of Biopolymer-Assisted Drug Delivery: Advancements, Clinical Applications, and Future Perspectives in Cancer Nanomedicine

Alharbi, H. M. (2024) · Drug Design, Development and Therapy · doi:10.2147/dddt.s441325 · Cited by 22 · see citing works

The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study

Garufi, A., Pistritto, G., D’Orazi, V., Cirone, M., & D’Orazi, G. (2022) · Biomolecules · doi:10.3390/biom12030461 · Cited by 30 · see citing works

Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeutics

Yousuf, M., Shamsi, A., Khan, S., Κhan, P., Shahwan, M. J., Elasbali, A. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.013 · Cited by 33 · see citing works

DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β

Zhou, L., Yao, N., Yang, L., Liu, K., Qiao, Y., Huang, C., Du, R., Yeung, Y. T., Liu, W., Cheng, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112445 · Cited by 29 · see citing works

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway

Liu, Z., Liu, C., Yan, K., Liu, J., Fang, Z., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.615568 · Cited by 29 · see citing works

Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer

Harachi, M., Masui, K., Cavenee, W. K., Mischel, P. S., & Shibata, N. (2021) · Metabolites · doi:10.3390/metabo11040216 · Cited by 29 · see citing works

Optimized data-independent acquisition approach for proteomic analysis at single-cell level

Wang, Y., Lih, T. M., Chen, L., Xu, Y., Kuczler, M. D., Cao, L., Pienta, K. J., Amend, S. R., & Zhang, H. (2022) · Clinical Proteomics · doi:10.1186/s12014-022-09359-9 · Cited by 29 · see citing works

Quantitative Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative Breast Cancer Cells

Ashrafian, S., Zarrineh, M., Jensen, P., Nawrocki, A., Rezadoost, H., Ansari, A. M., Farahmand, L., Ghassempour, A., & Larsen, M. R. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00168 · Cited by 28 · see citing works

Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor In Situ Fluid

Sheng, Z., Yu, J., Deng, K., Andrade-Barazarte, H., Zemmar, A., Li, S., Li, N., Yan, Z., Chen, Z., Sun, Y. Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.584988 · Cited by 28 · see citing works

SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer

Xia, Q., Sun, J., Xun, Y., Xiao, J., Liu, C., Xu, J., An, Y., Xu, M., Liu, Z., Wang, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864156 · Cited by 28 · see citing works

Amomum subulatum: A treasure trove of anti-cancer compounds targeting TP53 protein using in vitro and in silico techniques

Ali, S., Noreen, A., Qamar, A., Zafar, I., Ain, Q., Nafidi, H., Jardan, Y. A. B., Bourhia, M., Rashid, S., & Sharma, R. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1174363 · Cited by 28 · see citing works

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer

Sirhan, Z., Alojair, R., Thyagarajan‐Sahu, A., & Sahu, R. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082090 · Cited by 28 · see citing works

Harnessing the therapeutic potential of extracellular vesicles for cancer treatment

Zhang, Y., Xiao, Y., Sun, G., Jin, X., Guo, L., Li, T., & Yin, H. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.001 · Cited by 27 · see citing works

Significance of African Diets in Biotherapeutic Modulation of the Gut Microbiome

Isibor, P. O., Akinduti, P. A., Aworunse, O. S., Oyewale, J., Oshamika, O. O., Ugboko, H. U., Taiwo, O., Ahuekwe, E. F., Obafemi, Y. D., Onibokun, E. A., et al. (2021) · Bioinformatics and Biology Insights · doi:10.1177/11779322211012697 · Cited by 30 · see citing works

Ubiquitination and SUMOylation: Protein Homeostasis Control Over Cancer

Dai, X., Zhang, T., & Hua, D. (2021) · Epigenomics · doi:10.2217/epi-2021-0371 · Cited by 27 · see citing works

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment

Papatheofani, V., Levidou, G., Sarantis, P., Koustas, E., Karamouzis, M. V., Pergaris, A., Kouraklis, G. P., & Theocharis, S. E. (2021) · Biomedicines · doi:10.3390/biomedicines9020119 · Cited by 26 · see citing works

Virulence of Vibrio alginolyticus Accentuates Apoptosis and Immune Rigor in the Oyster Crassostrea hongkongensis

Mao, F., Liu, K., Wong, N.-K., Zhang, X., Yi, W., Xiang, Z., Xiao, S., Yu, Z., & Zhang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746017 · Cited by 26 · see citing works

Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma

Planas‐Paz, L., Pliego‐Mendieta, A., Hagedorn, C., Aguilera‐Garcia, D., Haberecker, M., Arnold, F. M., Herzog, M., Bankel, L., Guggenberger, R., Steiner, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216863 · Cited by 26 · see citing works

Colorectal cancer: the APC-lncRNA link

Morin, P. J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125985 · Cited by 25 · see citing works

SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone

Gomarasca, M., Lombardi, G., & Maroni, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.889002 · Cited by 25 · see citing works

JARID2 coordinates with the NuRD complex to facilitate breast tumorigenesis through response to adipocyte‐derived leptin

Liu, W., Zeng, Y., Hao, X., Wang, X., Liu, J., Gao, T., Wang, M., Zhang, J., Huo, M., Hu, T., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12479 · Cited by 25 · see citing works

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

Hu, Q., Shi, Y., Wang, H., Li, B., & Xu, Z. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00627-6 · Cited by 26 · see citing works

Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases

Offermann, A., Kang, D., Watermann, C., Weingart, A., Hupe, M. C., Saraji, A. A., Stegmann-Frehse, J., Kruper, R., Schüle, R., Pantel, K., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab083 · Cited by 24 · see citing works

E3 ubiquitin ligase TRIM31: A potential therapeutic target

Deng, N.-H., Tian, Z., Zou, Y.-J., & Quan, S.-B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116846 · Cited by 23 · see citing works

Catalpol Ameliorates Neurotoxicity in N2a/APP695swe Cells and APP/PS1 Transgenic Mice

Du, J., Liu, J., Huang, X., Li, Y., Song, D., Li, Q., Lin, J., Li, B., & Li, L. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00524-4 · Cited by 23 · see citing works

Plasma exosome-derived circGAPVD1 as a potential diagnostic marker for colorectal cancer

Li, T., Zhou, T., Wu, J., Lv, H., Zhou, H., Du, M., Zhang, X., Wu, N., Gong, S., Ren, Z., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101652 · Cited by 23 · see citing works

Post-translational modifications on the retinoblastoma protein

Zhou, L., Ng, D. S., Yam, J. C. S., Chen, L. J., Tham, C. C. Y., Pang, C. P., & Chu, W. K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00818-x · Cited by 64 · see citing works

Role of post-translational modifications in regulation of tumor suppressor p53 function

Che, Z., Sun, H., Yao, W., Lü, B., & Han, Q. (2020) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm.2019.12.02 · Cited by 8 · see citing works

Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors

Xu, W., Zhen, Y., Zhou, S., & Lü, N. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s71061 · Cited by 59 · see citing works

Posttranslational Modifications of the Retinoblastoma Tumor Suppressor Protein as Determinants of Function

MacDonald, J. I., & Dick, F. A. (2012) · Genes & Cancer · doi:10.1177/1947601912473305 · Cited by 69 · see citing works

p53: The Multifaceted Roles of Covalent Modifications in Cancer

Grigoreva, T. A., Romanova, A. A., Tribulovich, V. G., Pestov, N. B., Oganov, R. A., Kovaleva, D. K., Korneenko, T. V., & Barlev, N. A. (2024) · Pharmaceuticals · doi:10.3390/ph17121682 · Cited by 10 · see citing works